

# Broadgate Advises Boston Oncology Arabia on USD 35 Million Investment from TVM Capital

*Investment Expected to Expedite Boston Oncology Arabia's Move into Full Formulation and Fill and Finish Manufacturing*

RIYADH , CENTRAL, KINGDOM OF SAUDI ARABIA, July 1, 2024

/EINPresswire.com/ -- [Broadgate](#)

Advisers (“Broadgate”) has successfully advised Boston Oncology Arabia (the “Company” or “[BOA](#)”), a leading bio-generic drugs manufacturing company based in Saudi Arabia, on a USD35 million investment from [TVM](#) Capital Healthcare (“TVM”).



Broadgate Logo

From its headquarters in Riyadh and production facility in Sudair Industrial City, BOA provides vital medicines for critical conditions through the local development and manufacturing of internationally licensed, best-in-class therapeutics. The Company is contributing to a key goal of Saudi Arabia’s Vision 2030 by supplying critical care medicines through highly flexible, local manufacturing facilities and leveraging its international relationships for licensing from Western and Eastern markets.



The high level of interest generated from various strategic and financial investors demonstrated the strong global appetite for investments in KSA in general, and the healthcare sector in particular”

*Habib Aoun*

TVM will expedite BOA’s move into full formulation and fill and finish manufacturing, and will provide strategic support and leverage its global network to further expand the Company’s access to international suppliers.

Abdullah Baaj, MD, PharmD, Founder & CEO of BOA, commented: “Boston Oncology Arabia’s localization model

is specifically designed to create value in complex and competitive markets. TVM’s enables us to strengthen our position and bring cutting-edge, specialized manufacturing to the GCC and MENA region, impacting the lives of millions of patients.”

Orhan Osmansoy, Managing Partner at TVM Capital Healthcare, said: "As a fast-growing local bio-generics manufacturer, Boston Oncology Arabia is playing a major role in developing Saudi's pharmaceutical sector. With an impressive management team, the company is the established leader in therapeutics for oncology and critical care. We are pleased to be on this journey with our co-investors Kanoo Ventures, as Boston Oncology Arabia helps to increase local production, reduce healthcare costs, and improve access to essential pharmaceuticals in the Kingdom."

Habib Aoun, Head of M&A Advisory at Broadgate, added: "We are proud to have advised Boston Oncology Arabia since its early stages of growth, leading up to this successful transaction with TVM. The high level of interest generated from various strategic and financial investors throughout the process demonstrated the strong global appetite for investments in Saudi Arabia in general, and in the healthcare sector in particular."

Habib Aoun  
Broadgate Advisers  
ha@broadgate.ch

Visit us on social media:

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/723777695>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.